See how easy it is when you don't screw up - twice! So Purdue get two abuse Oxy's approved whilst we are left with two CRLs. It's a wonder that Remi is still earning millions every year.
Barbier alluded to this possibility several times in the course of PTIE's Q1 conference call.
News on yet another experimental approach to refine the diagnostic process for the detection of early-onset Alzheimer's Disease (from the WSJ 7/13/14):
COPENHAGEN—Efforts to detect Alzheimer's disease earlier and more cheaply are focusing on signs of the ailment in the eye and sense of smell.
Scientists have found that certain biological changes in the retina and lens of the eye, and in the sense of smell, may help predict whether people with no or minor memory issues may go on to develop the progressive brain disease, according to findings presented here Sunday at the Alzheimer's Association International Conference.
Alzheimer's disease is diagnosed primarily by clinical examination using memory tests and questions about how a patient is functioning. But researchers are attempting to devise tools, particularly using biological markers, to improve the detection of early stages of the disease, said David Knopman, a neurologist at Mayo Clinic and a member of the Alzheimer's Association Medical and Scientific Advisory Council.
The disease's pathology in the brain typically begins decades before the appearance of memory symptoms.
Looking for changes in the eye or smell represent "simpler, less invasive" methods that are more feasible for use in doctor's offices and other clinical settings, Dr. Knopman said.
Since there aren't yet any treatments that stop the progression of Alzheimer's—and some people may not want to know they face a devastating disease without a cure—earlier detection primarily could be helpful for research purposes in identifying people who are good candidates to participate in prevention trials and to monitor brain changes that occur as the disease progresses.
Many experimental disease-modifying treatments are under development. Once such a treatment is available, the hope is to identify people at greater risk of Alzheimer's and give them the treatment before they exhibit memory symptoms.
Currently, brain imaging can be used to detect one major pathology associated with the disease—clumped deposits of the protein amyloid—but it is expensive and used primarily for research, not in doctors' offices.
Efforts to develop blood-based tests for Alzheimer's generate much excitement among the public but none are ready for prime time yet, experts say.
But amyloid plaques found in the brain also are known to be deposited in the eye. Two company-funded studies found that those deposits can be detected through noninvasive eye-imaging technology and are highly correlated with the amyloid results from brain imaging.
Cognoptix Inc., a closely held biotech company in Acton, Mass., focuses on amyloid detection in the lens of the eye. CSIRO Australia, the country's national science agency, and its Sacramento, Calif.-based partner, NeuroVision Imaging LLC, have been studying the retina, in the back of the eyes.
The retina is like a "piece of brain outside the brain," said Shaun Frost, a researcher at CSIRO Australia.
The first 40 patients in a 200-participant study showed that retina changes correlated strongly with amyloid plaque development in the brain. The full study will be completed this year, according to Dr. Frost.
It remains to be seen whether eye imaging will prove better than memory tests at detecting Alzheimer's. There has been limited research to track whether early signals in the eye actually predict development of the disease.
Smell is another area of interest because the odor center of the brain appears particularly vulnerable to Alzheimer's pathology and the ability to identify different smells becomes impaired relatively early in the disease process.
A study of some 1,000 individuals without Alzheimer's diagnoses who were examined from 2004 to 2006, using a simple scratch-and-sniff smell test known as the UPSIT, showed that lower scores on the test were associated with a greater risk of developing Alzheimer's—even if the individual was cognitively normal at the beginning of the study, said Davangere Devanand, a Columbia University psychology and psychiatry professor.
Researchers cautioned that more work is needed and that a number of other factors can influence smell, including smoking and ailments such as Parkinson's and schizophrenia.
Let's not get carried away here. From the WSJ OnLine dated 7/8/14:
LONDON—Shares in British biotech group Proteome Sciences PLC rose sharply Tuesday after the company made what it called a "significant step" toward developing a blood test for Alzheimer's.
In a study co-written with researchers from King's College London, the company said it has identified a set of 10 proteins in blood that can predict the onset of Alzheimer's, the most common form of dementia.
There is currently no accurate way to predict who will develop Alzheimer's and no long-lasting drug treatments for those affected. Brain-imaging and tests of cerebrospinal fluid can show signs of the disease's progression, but a blood test would be simpler, cheaper and less invasive.
Proteome shares jumped 17% to $38.50 in London trading.
The study, published Tuesday in the journal Alzheimer's & Dementia, took blood samples from 1,148 people in three countries, comprising 476 with Alzheimer's, 220 with mild cognitive impairment and 452 elderly patients with no dementia symptoms.
Researchers said the 10 proteins they have identified can predict with 87% accuracy whether someone with mild cognitive impairment will develop Alzheimer's within a year.
A number of other companies have been working on blood-protein tests for Alzheimer's in recent years, with varied results. U.K. Secretary of State for Health Jeremy Hunt called the findings of the latest study "welcome research on an issue we have made a national priority."
Dementia experts welcomed the Proteome study findings but cautioned that they need to be replicated in larger groups of people and that a test for Alzheimer's is likely to be many years away.
"The results reported today are interesting but as the authors point out there is still a very large amount of work remaining until a usable blood test for Alzheimer's disease becomes available," said Adrian Pini, a senior lecturer at King's College.
"These 10 proteins can predict conversion to dementia with less than 90% accuracy, meaning one in 10 people would get an incorrect result," said James Pickett, head of research at the Alzheimer's Society. "Therefore, accuracy would need to be improved before it could be a useful diagnostic test."
Identifying patients likely to develop the disease earlier is one of the priorities of Alzheimer's research.
This is partly so drug companies can select the right people to participate in clinical trials of experimental drugs in development.
"Alzheimer's begins to affect the brain many years before patients are diagnosed with the disease. Many of our drug trials fail because by the time patients are given the drugs, the brain has already been too severely affected," said Simon Lovestone, a senior author of the study.
Developing a treatment for Alzheimer's is one of the big untapped opportunities for drug companies, but progress has been achingly slow over the last decade. A number of high-profile failures in late-stage trials have led many companies to exit the field.
Merck & Co. and AstraZeneca PLC are working on late-stage trials of experimental Alzheimer's drugs in development, but the latter gives its compound just a 9% chance of success.
"Since there is as yet no cure for Alzheimer's, learning later that you have the disease is preferable to finding out early. The test needs to be backed up by work on drugs which may halt the progress of the disease," said Doctor Jackson, a professor at Birmingham City University.
Research into drugs targeting the brain and central nervous system makes up just 15% of the industry's projects, estimates Barclays, despite the disproportionate cost to national health systems.
AAW - good detective work. That would certainly be a most interesting development and would warrant Remi's claim that this would be a much bigger deal than Remoxy. I read last week that PRM in the UK have developed a blood test that can detect AD years before symptoms show with 87% accuracy. This test will be used by all major pharmas to trial new AD drugs at a much earlier stage than is presently possible. A perfect combination perhaps.
Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy